Ph.D. | Research Director
- Health economic evaluations
- Cost-Effectiveness simulation modeling
- Economic simulation modeling
- Cost-Effectiveness of Diabetes Mellitus and obesity interventions
- Willingness-to-Pay and Qol
- Diabetes Mellitus (Type 1 and Type 2)
- Obesity and Overweight
- Parkinson’s Disease
“Impact on Schizophrenia Inpatient Resource Use Following Switch to Long-Acting Risperidone in Finland”, ISPOR 11th Annual European Congress, Athens, Greece, November 9-11, 2008. Mickael Löthgren, Christian Asseburg, Michael Willis, Niko Seppäla, Mika Hakala, Marianne Svensson, and Ulf Persson.
“The Cost-Effectiveness of the Early Insulin Use Treatment Pathway in the ADA/EASD Joint Consensus Algorithm for the Treatment of Type 2 Diabetes”, Poster presentation at the American Diabetes Association’s 68th Scientific Sessions, San Francisco, June 6-10, 2008.MichMichael Willis, Christian Asseburg, Cheryl Neslusan,, and Ulf Persson
“Impact of Switch to Long-Acting Risperdal Consta on Inpatient Resource Use for Treating Schizophrenia in Sweden”, 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 2-7, 2008. A.Berntsson, M. Willis, M. Svensson, U. Persson, B. Eriksson, M. Löthgren.
“Cost-Effectiveness of Strict ‘Get To Goal’ Treatment Directives in the Treatment of Younger Patients with Newly Diagnosed Type 2 Diabetes Mellitus, Presented at the 9th Annual ISPOR European Congress, Dublin, Ireland, October 20-23, 2007. Michael Willis, Christian Asseburg, Sixten Borg, Ulf Persson, and Cheryl Neslusan.
“Economic Modeling of a Chronic, Progressive Disease: The History, Challenges, and Lessons Learned from Diabetes Mellitus”, Panel session presentation at the International Health Economics Association’s 6th World Congress, Copenhagen, Denmark, July 8-11, 2007.
“Cost-Effectiveness of Sulfonylureas versus Metformin as First-Line Therapy in Newly Diagnosed Type 2 Diabetes”, Poster presentation at the 67th Scientific Sessions of the American Diabetes Association, Chicago, Illinois, June 22-26, 2007.
"The Cost-Effectiveness of Calcium and Vitamin D3 Supplementation for the Prevention of Osteoporotic Hip Fractures in Sweden" Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference, Cannes, France, November 10-13, 2001.
“The Health Economics of Treating CVD Risk Factors in Type 2 DM: Cost-Effectiveness Studies from UKPDS, 4S, and HOPE”, presentation for The Atherosclerotic Process: Inflammation, Diabetes, and Cost-Effectiveness, Malmö, Sweden, October 25, 2000.
“The Introduction of Crack Cocaine and the Rise in Urban Crime Rates”, presentation for the World Bank’s International Conference on Crime and Violence: Causes and Policy Responses, Bogota, Columbia, May 4-5, 2000.
“Economics of a New Treatment for Diabetic Foot Ulcers: The Cost-Effectiveness of Becaplermin in Sweden”, Poster presentation at European Association for the Study of Diabetes (EASD) Conference, Brussels, Belgium, September 28-October 2, 1999.
“Economics of a New Preventative Therapy for Osteoporotic Fractures: The Cost-Effectiveness of Livial in Sweden”, Paper presented at Nordic Health Economists’ Study Group, Reykjavik, Iceland, August 20-21, 1999.
“The Health Economics of Calcium and Vitamin D3 for the Prevention of Osteoporotic Hip Fractures in Sweden”, International Journal of Technology Assessment in Health Care 18 (Winter 2002): 861-877.
“Cost-Effectiveness of Tibolone in the Prevention of Osteoporotic Fractures After the Menopause”, Menopause Digest 14 (2002): 12-14.
”Cost-Effectiveness of Treating Deep Diabetic Foot Ulcers with Promogran in Four European Countries”, Journal of Wound Care 11 (February 2002): 70-74.
“Cost-Effectiveness of Becaplermin (Regranex) in the Treatment of Diabetic Foot Ulcers in Four European Countries", PharmacoEconomics 7 (2001): 767-778.
“A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden”, Clinical Drug Investigations 21 (2001): 115-127.
“The Cost-Effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex): A Core Model with an Application using Swedish Cost Data”, Value in Health 3 (Supplement 1 2000): S39-S46.
“The Emergence of Crack Cocaine and Rises in Urban Crime”, The Review of Economics and Statistics 82 (November 2000): 519-529.
“The Cost-Effectiveness in the UK of Treating Lower Extremity Ulcers with Becaplermin Gel”, Journal of Medical Economics 3 (2000): 87-95.
“International Comparison of Health Care Systems Using Resource Profiles”, Bulletin of the World Health Organization 17 (Special Issue 2000): 175-185.
“Sjukhus i förändring: Jämförande studie av Uddevalla sjukhus, Princess Royal Hospital och Henry Ford Hospital (Hospitals in Change: A Comparison Study of Uddevalla Hospital, Princess Royal Hospital, and Henry Ford Hospital)”, IHE Working Paper 1999:5, 1999.
”Leading Firm Asymmetry as a Determinant of Advertising Intensity”, Review of Industrial Organization 13 (August 1998): 495-508.